Abstract 1194P
Background
Artificial intelligence (AI) based on deep learning and convolutional neural networks (CNN) has been applied to various medical fields. We are developing a novel AI system to support the detection of lung cancer, which will enable physicians to efficiently interpret radiograms and perform diagnosis.
Methods
For training data, we analyzed the image features of 800 chest X-ray images (acquired mainly for lung cancer screening; 400 normal images and 400 abnormal images) from Fukushima Preservative Service Association of Health and 5 000 chest radiographs from the National Institutes of Health (NIH) database. We categorized these data into two groups. Group A included both 800 images and NIH database, and group B included only 800 images. Then, using ImageNet, we used these datasets to develop a proprietary AI algorithm with deep learning and a CNN, and analyzed the statistical accuracy of interpretations of the radiograms. We also demonstrated abnormal shadow in the form of a heat map display on each chest radiograph for easy visualization, and presented the positive probability score as an index value from 0.0 to 1.0 indicating the possibility of lung cancer. The accuracy of our AI system was improved by using technology to account for differences in radiographic apparatus and imaging environments.
Results
Using a positive probability cutoff value of 0.5, our novel AI showed an area under the curve (AUC) of 0.74, sensitivity of 0.75, and specificity of 0.60 for group A, and AUC of 0.79, sensitivity of 0.72, and specificity of 0.74 for group B. The accuracy on both groups was superior to that of radiologists (AUC 0.72), and was also compatible with previous study reports (AUC 0.67-0.78). The number of training data did not make a difference in accuracy. The heat map display was also clearly demonstrated on the monitor screen if a roentgenogram had abnormal shadows.
Conclusions
In this study, we confirmed that our proprietary AI system had a similar accuracy in the interpretation of chest radiographs to that of previous studies and radiologists. However, further research and improvement is needed to verify the accuracy. We are now in the process of performing various types of validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grants-in-Aid for Scientific Research in Japan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
697P - The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors
Presenter: Robert Holwell
Session: Poster session 09
698P - Outcomes of patients with testicular germ cell tumors in Latin-America
Presenter: Saul Campos Gomez
Session: Poster session 09
699P - Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) trial: Three year update
Presenter: Axel Heidenreich
Session: Poster session 09
701P - Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
Presenter: Hedyeh Ebrahimi
Session: Poster session 09
702P - Survival and related factors in testicular non-seminomatous patients undergoing high-dose chemotherapy and autologous stem cell transplantation: Experience of Turkey's highest volume transplantation center
Presenter: Musa Baris Aykan
Session: Poster session 09
703P - Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER
Presenter: Adam Kolawa
Session: Poster session 09
704P - Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study
Presenter: Christoph Oing
Session: Poster session 09
705P - Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers
Presenter: Sruthi Vellanki
Session: Poster session 09
706P - Stereotactic radiosurgery (SRS) in brain metastases (BMs) from non-seminomatous germ cell tumours (NSCGTs)
Presenter: Deep Chakrabarti
Session: Poster session 09